We hypothesize that the addition of IL-2, anti-CTLA-4, or anti-PD-1/PD-L1 may reinforce CD8+ T cell function in the tumor microenvironment to further ameliorate antitumor efficacy of M-ILP. The gene discussed is CD8A; the disease is neoplasm.